Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 341

1.

A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes.

Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC.

J Infect Dis. 2016 Sep 21. pii: jiw431. [Epub ahead of print]

PMID:
27655868
2.

Thermo-Responsive Polymer Nanoparticles Co-Deliver RSV F Trimers with a TLR-7/8 Adjuvant.

Francica JR, Lynn GM, Laga R, Joyce MG, Ruckwardt TJ, Moribito KM, Chen M, Chaudhuri R, Zhang B, Sastry M, Ko K, Choe M, Pechar M, Georgiev IS, Kueltzo LA, Seymour LW, Mascola JR, Kwong PD, Graham BS, Seder RA.

Bioconjug Chem. 2016 Sep 1. [Epub ahead of print]

PMID:
27583777
3.

Packaging and prefusion stabilization separately and additively increase the quantity and quality of RSV-neutralizing antibodies induced by respiratory syncytial virus (RSV) fusion protein expressed by a parainfluenza vector.

Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2016 Aug 31. pii: JVI.01196-16. [Epub ahead of print]

PMID:
27581977
4.

Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.

Roberts JN, Graham BS, Karron RA, Munoz FM, Falsey AR, Anderson LJ, Marshall V, Kim S, Beeler JA.

Vaccine. 2016 Sep 22;34(41):4843-9. doi: 10.1016/j.vaccine.2016.07.057. Epub 2016 Aug 25.

PMID:
27566900
5.

Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith AR, Goo L, Platt DJ, Mascola JR, Graham BS, Mulligan MJ, Diamond MS, Ledgerwood JE, Pierson TC.

Cell Rep. 2016 Aug 9;16(6):1485-91. doi: 10.1016/j.celrep.2016.07.049. Epub 2016 Jul 29.

6.

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.

Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet EJ, Tsybovsky Y, Yang Y, Georgiev IS, Guttman M, Lees CR, Pancera M, Sastry M, Soto C, Stewart-Jones GB, Thomas PV, Van Galen JG, Baxa U, Lee KK, Mascola JR, Graham BS, Kwong PD.

Nat Struct Mol Biol. 2016 Sep;23(9):811-20. doi: 10.1038/nsmb.3267. Epub 2016 Aug 1.

PMID:
27478931
7.

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.

Boyington JC, Joyce MG, Sastry M, Stewart-Jones GB, Chen M, Kong WP, Ngwuta JO, Thomas PV, Tsybovsky Y, Yang Y, Zhang B, Chen L, Druz A, Georgiev IS, Ko K, Zhou T, Mascola JR, Graham BS, Kwong PD.

PLoS One. 2016 Jul 27;11(7):e0159709. doi: 10.1371/journal.pone.0159709. eCollection 2016.

8.

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, Zhang B, Zhang Y, Asokan M, Boyington JC, Bylund T, Darko S, Lees CR, Ransier A, Shen CH, Wang L, Whittle JR, Wu X, Yassine HM, Santos C, Matsuoka Y, Tsybovsky Y, Baxa U; NISC Comparative Sequencing Program, Mullikin JC, Subbarao K, Douek DC, Graham BS, Koup RA, Ledgerwood JE, Roederer M, Shapiro L, Kwong PD, Mascola JR, McDermott AB.

Cell. 2016 Jul 28;166(3):609-23. doi: 10.1016/j.cell.2016.06.043. Epub 2016 Jul 21.

PMID:
27453470
9.

Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection.

Jacobino SR, Nederend M, Hennus M, Houben ML, Ngwuta JO, Viveen M, Coenjaerts FE, Hack CE, van Neerven RJ, Graham BS, Bont L, Leusen JH.

J Allergy Clin Immunol. 2016 Jun 16. pii: S0091-6749(16)30496-1. doi: 10.1016/j.jaci.2016.06.001. [Epub ahead of print] No abstract available.

PMID:
27448445
10.

A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.

Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JC, Moin SM, Graham BS, Piedra PA, Moore ML.

J Virol. 2016 Jul 27;90(16):7508-18. doi: 10.1128/JVI.00012-16. Print 2016 Aug 15.

PMID:
27279612
11.

Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA; VRC 312 and VRC 314 Study Teams.

Nat Med. 2016 Jun 7;22(6):692. doi: 10.1038/nm0616-692c. No abstract available.

PMID:
27270781
12.

Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung.

Morabito KM, Ruckwardt TR, Redwood AJ, Moin SM, Price DA, Graham BS.

Mucosal Immunol. 2016 May 25. doi: 10.1038/mi.2016.48. [Epub ahead of print]

PMID:
27220815
13.

Vaccines against respiratory syncytial virus: The time has finally come.

Graham BS.

Vaccine. 2016 Jun 24;34(30):3535-41. doi: 10.1016/j.vaccine.2016.04.083. Epub 2016 May 13.

PMID:
27182820
14.

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA.

Nat Med. 2016 Jun;22(6):614-23. doi: 10.1038/nm.4110. Epub 2016 May 9.

PMID:
27158907
15.

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.

Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, Reed J, Sutton WF, Hammond KB, Cheever TA, Barnette PT, Legasse AW, Planer S, Stanton JJ, Pegu A, Chen X, Wang K, Siess D, Burke D, Park BS, Axthelm MK, Lewis A, Hirsch VM, Graham BS, Mascola JR, Sacha JB, Haigwood NL.

Nat Med. 2016 Apr;22(4):362-8. doi: 10.1038/nm.4063. Epub 2016 Mar 21.

16.

Determinants of early life immune responses to RSV infection.

Ruckwardt TJ, Morabito KM, Graham BS.

Curr Opin Virol. 2016 Feb;16:151-7. doi: 10.1016/j.coviro.2016.01.003. Epub 2016 Mar 15. Review.

17.

A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology.

Liu J, Haddad EK, Marceau J, Morabito KM, Rao SS, Filali-Mouhim A, Sekaly RP, Graham BS.

PLoS Pathog. 2016 Mar 4;12(3):e1005486. doi: 10.1371/journal.ppat.1005486. eCollection 2016 Mar.

18.

Pre-fusion structure of a human coronavirus spike protein.

Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB.

Nature. 2016 Mar 3;531(7592):118-21. doi: 10.1038/nature17200.

19.

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ.

Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.

PMID:
26917593
20.

Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS.

Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.

PMID:
26917592
Items per page

Supplemental Content

Loading ...
Write to the Help Desk